Aviva PLC Boosts Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Aviva PLC lifted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 215.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 77,244 shares of the biopharmaceutical company's stock after purchasing an additional 52,738 shares during the quarter. Aviva PLC owned 0.06% of Alnylam Pharmaceuticals worth $18,176,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of ALNY. Larson Financial Group LLC lifted its position in Alnylam Pharmaceuticals by 187.2% during the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 73 shares during the last quarter. R Squared Ltd bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth $33,000. OFI Invest Asset Management purchased a new position in Alnylam Pharmaceuticals in the fourth quarter worth $35,000. Versant Capital Management Inc increased its stake in Alnylam Pharmaceuticals by 77.6% in the fourth quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company's stock valued at $45,000 after acquiring an additional 83 shares during the last quarter. Finally, IFP Advisors Inc increased its stake in Alnylam Pharmaceuticals by 24.2% in the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock valued at $57,000 after acquiring an additional 47 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Insider Activity

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 52,592 shares of the firm's stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the sale, the chief marketing officer now directly owns 11,989 shares in the company, valued at approximately $3,416,865. This trade represents a 81.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Jeffrey V. Poulton sold 967 shares of the company's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $246,749.39. Following the completion of the transaction, the chief financial officer now directly owns 32,786 shares in the company, valued at $8,366,003.62. This trade represents a 2.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 71,234 shares of company stock worth $19,958,097. Insiders own 1.50% of the company's stock.

Remove Ads

Alnylam Pharmaceuticals Trading Up 5.1 %

NASDAQ ALNY traded up $11.49 during trading on Friday, hitting $237.77. The company had a trading volume of 1,577,336 shares, compared to its average volume of 865,144. The company's fifty day moving average is $253.20 and its 200-day moving average is $258.26. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The company has a market cap of $30.93 billion, a price-to-earnings ratio of -109.57 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ALNY. Stifel Nicolaus lifted their price target on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a "buy" rating in a research note on Monday, March 31st. Chardan Capital reaffirmed a "buy" rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Sanford C. Bernstein decreased their price target on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating on the stock in a research note on Tuesday, January 7th. JPMorgan Chase & Co. upgraded shares of Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and boosted their price objective for the stock from $280.00 to $328.00 in a report on Monday, March 24th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $500.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 2nd. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $315.58.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.